Difference between revisions of "Lenalidomide (Revlimid)"
m |
|||
Line 6: | Line 6: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Patient drug information== | ==Patient drug information== | ||
Line 33: | Line 24: | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Immunomodulatory drugs (IMiDs)]] | [[Category:Immunomodulatory drugs (IMiDs)]] | ||
+ | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
+ | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
+ | [[Category:Follicular lymphoma medications]] | ||
+ | [[Category:Light-chain (AL) amyloidosis medications]] | ||
+ | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
+ | [[Category:Myelodysplastic syndrome medications]] |
Revision as of 20:09, 17 May 2014
General information
Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to Thalidomide (Thalomid); mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.[1][2][3][4]
Route: PO
Extravasation: n/a
- Use of Lenalidomide (Revlimid) requires participation the RevAssist program.[4]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Lenalidomide (Revlimid) package insert PDF pages 28-33[1]
- Lenalidomide (Revlimid) patient medication guide[5]
- Lenalidomide (Revlimid) patient drug information (Chemocare)[6]
- Lenalidomide (Revlimid) patient drug information (UpToDate)[7]
History of changes in FDA indication
- 12/28/2005: FDA approved for patients with "transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities."[1]
- 6/29/2006: FDA approved for treatment of patients with "multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy.][1]
- 6/5/2013: FDA approved for patients with "mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Lenalidomide (Revlimid) package insert
- ↑ Lenalidomide (Revlimid) package insert (locally hosted backup)
- ↑ Revlimid manufacturer's site
- ↑ 4.0 4.1 RevAssist program
- ↑ Lenalidomide (Revlimid) patient medication guide
- ↑ Lenalidomide (Revlimid) patient drug information (Chemocare)
- ↑ Lenalidomide (Revlimid) patient drug information (UpToDate)
- Drug index
- Chemotherapy
- Immunomodulatory drugs (IMiDs)
- Aggressive Non-Hodgkin lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Follicular lymphoma medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Multiple myeloma medications
- Myelodysplastic syndrome medications